Detalles de la búsqueda
1.
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
J Allergy Clin Immunol
; 143(1): 135-141, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29906525
2.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Clin Pharmacol Drug Dev
; 13(6): 665-671, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523487
3.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Clin Pharmacol Ther
; 115(3): 565-575, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38115209
4.
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
ERJ Open Res
; 9(5)2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37868151
5.
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Sci Transl Med
; 11(489)2019 04 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31019027
6.
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
J Psychopharmacol
; 26(5): 653-62, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048884
Resultados
1 -
6
de 6
1
Próxima >
>>